Protic Marijana, Markovic Srdjan, Tarabar Dino
Department of Gastroenterology, University Hospital Zvezdara, Belgrade, Serbia.
Dig Dis. 2017;35(1-2):134-138. doi: 10.1159/000449094. Epub 2017 Feb 1.
Although severe flare of ulcerative colitis (UC) is uncommon, it significantly increases the risk of preterm delivery, low birth weight and other adverse fetal outcomes. It is critical to optimize aggressive medical treatment with both mother and fetal health. Here, we present a case of a 30-year-old woman with a severe flare of UC at the 16th gestational week. The diagnosis of extensive UC was established 8 years ago. From the time she was diagnosed, she had 5 moderate flares successfully treated with oral and topical mesalamine. The relapses of disease occurred due to poor adherence to maintenance therapy. The patient had a positive family history for UC and thrombophilia (factor V Leiden mutations). At the time of admission, she presented with 8-10 bloody diarrheas and moderate abdominal pain. She was afebrile with increased heart rate (96/min). Laboratory studies showed elevated C-reactive protein (CRP, 42 mg/l), fecal-calprotectin (7,223 μg/g), and anemia (hemoglobin 10.4 g/dl). Clostridium difficile and CMV infection were excluded. Intensive treatment with systemic steroids and low-molecular weight heparin was started. Three days later, no response to the therapy was observed (8 bloody stools, CRP 40 mg/l). According to emergency symptoms, rescue therapy with infliximab (IFX; 5 mg/kg standard induction protocol) was administered a week later. A partial clinical and laboratory response was achieved after the second dose of IFX (4 stools/day, CRP 12.2 mg/l and FCP 1,078 μg/g). The patient received the third and least doses of IFX at the 23rd gestational week. She continued on corticosteroids and mesalamine with chronically active moderate disease. IFX trough levels before the third dose were 20.6 μg/ml; antibodies to IFX were negative. The patient delivered trans-vaginally a healthy girl on the 36th gestational week (the newborn weight: 3,150 kg, APGAR score 9). No live vaccines were administrated to the newborn until 6 months of age.
尽管溃疡性结肠炎(UC)的严重发作并不常见,但它会显著增加早产、低出生体重和其他不良胎儿结局的风险。优化积极的药物治疗对母亲和胎儿的健康至关重要。在此,我们报告一例30岁女性,在妊娠第16周时发生UC严重发作。广泛性UC的诊断于8年前确立。自诊断以来,她有5次中度发作,通过口服和局部使用美沙拉嗪成功治疗。疾病复发是由于维持治疗依从性差。该患者有UC和易栓症(因子V莱顿突变)的家族史。入院时,她出现8 - 10次血性腹泻和中度腹痛。她无发热,但心率加快(96次/分钟)。实验室检查显示C反应蛋白(CRP,42mg/l)、粪便钙卫蛋白(7223μg/g)升高,且有贫血(血红蛋白10.4g/dl)。排除了艰难梭菌和巨细胞病毒感染。开始使用全身类固醇和低分子量肝素进行强化治疗。三天后,未观察到治疗反应(8次血性大便,CRP 40mg/l)。根据紧急症状,一周后给予英夫利昔单抗(IFX;5mg/kg标准诱导方案)进行抢救治疗。第二剂IFX后取得了部分临床和实验室反应(每天4次大便,CRP 12.2mg/l,FCP 1078μg/g)。患者在妊娠第23周接受了第三剂也是最后一剂IFX。她继续使用皮质类固醇和美沙拉嗪,病情为慢性活动性中度。第三剂之前的IFX谷浓度为20.6μg/ml;IFX抗体为阴性。患者在妊娠第36周经阴道分娩一名健康女婴(新生儿体重:3150kg,阿氏评分9分)。新生儿在6个月龄前未接种活疫苗。